Novo's pioneering diabetes pill impresses in first big study

COPENHAGEN/LONDON (Reuters) - The world's largest diabetes drugmaker, Novo Nordisk, on Thursday presented the first successful data from a large final-stage study of a pill it hopes will transform the diabetes market.